Mark Herrmann has details of Sinclair v. Merck.  The decision also suggests that the New Jersey Supreme Court is going to affirm the intermediate McDarby decision rejecting the use of consumer-fraud law for product-liability claims in New Jersey.

Filed under: class actions, medical monitoring, New Jersey, pharmaceuticals, Vioxx